Tag:

Roche

Latest Headlines

Latest Headlines

AstraZeneca reaches out to Roche with a would-be cancer blockbuster

AstraZeneca has high hopes for the in-development AZD9291, a treatment for lung cancer expected to bring in $3 billion a year at its peak, and the drugmaker is working with rival Roche to craft a blood test that can spot ideal patients for the therapy.

Roche, Novartis protest moves in EU to pay for off-label Avastin

Last week, France made its move to knock the Novartis eye drug Lucentis out of drug coverage and move its cheaper cousin Avastin into its place. Now, Novartis and its Lucentis partner Roche are fighting back.

Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly didn't cause the decline, with newcomers Perjeta and Kadcyla helping power the group with especially noteworthy revenue gains.

Avastin nabs second-in-a-row priority review, this time in ovarian cancer

Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer.

FDA fast-tracks Roche's Avastin for tough-to-treat ovarian cancer

Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's Avastin, which is now up for quick FDA approval of two new indications.

Roche CEO: No appetite for expensive megadeals here

Not every drug chief wants to ride the wave of M&A sweeping through pharma. Example: Roche CEO Severin Schwan, who says he'll stay in the shallows.

GlaxoSmithKline's melanoma combo beats Roche's Zelboraf in Phase III

GlaxoSmithKline is touting stellar Phase III results for an in-development combo therapy for melanoma, saying its treatment beat out Roche's Zelboraf in overall survival and led independent advisers to recommend an early end for the study.

Roche's Ventana inks deal with Merck KGaA to develop companion Dx for cancer

Personalized medicine is the latest trend in companion diagnostics, and companies are teaming up to develop comprehensive tests based on a patient's biologic characteristics. Roche's Ventana Medical Systems sees potential in the field, and recently inked a deal with Germany's Merck KGaA to develop a companion diagnostic test for different cancer indications.

Roche is at an Alzheimer's crossroads after mixed data for AC Immune's drug

An Alzheimer's treatment from AC Immune and Genentech posted mixed results in a midstage study, missing its coprimary endpoints but performing well in patients with milder symptoms. That leaves Roche, Genentech's parent company, with a big decision to make on whether to take the plunge into Phase III.

Roche's Avastin up for another lift with fast-track cervical cancer review

Roche's cancer blockbuster Avastin has yet another shot at boosting sales. The FDA put Avastin up for priority review in cervical cancer, with a decision date of Oct. 24.